Save up to 90% on Afatinib with Coupons, Discount Cards & Patient Assistance Programs

Afatinib is available as a 20 mg, 30 mg, and 40 mg oral tablet.

Afatinib is a kinase inhibitor and is used for the following:

• Non-small cell lung cancer (NSCLC) in people with:
• Metastatic NSCLC that have non-resistant mutations in the EGFR gene
• Metastatic squamous NSCLC that’ve gotten worse after receiving platinum therapy

Afatinib is a kinase inhibitor that works by attaching to these EGFR proteins. When it does, the proteins can’t continue to send signals for cancer cells to grow. This means cancer cells can’t grow and spread as well.

• Afatinib is typically taken as 40 mg taken by mouth once daily
• Your dose might be different if you’re also taking medications that can interact with Afatinib or have severe kidney problems

Afatinib is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Afatinib:

• Diarrhea
• Rash or acne-like bumps on the skin
• Painful sores in the mouth or throat
• Nail infection
• Higher liver enzyme levels
• Kidneys not working as well
• Low white blood cell counts
• Dry skin
• Low potassium levels
• Loss of appetite
• Nausea
• Itchy skin

Serious side effects are rare with Afatinib. Contact your healthcare provider immediately if you experience any of the following.

• Serious skin reactions: painful rash, blisters, peeling skin
• Lung problems: cough, fever, trouble breathing, shortness of breath, chest – pain
• Serious liver problems: tiredness, loss of appetite, nausea or vomiting, dark urine, right-side stomach pain, easy bruising or bleeding, or yellowing of the eyes or skin
• Tearing of the stomach or intestines: fever, chills, severe stomach pain, bloated stomach, nausea, vomiting
• Severe diarrhea

The following medications may interact with Afatinib:

• Co-administration of P-gp inhibitors can increase Afatinib exposure. Reduce Afatinib by 10 mg per day if not tolerated. Co-administration of chronic
• P-gp inducers orally can decrease Afatinib exposure. Increase Afatinib by 10 mg per day as tolerated

Various FDA-approved generic manufacturers

Based on findings from animal studies and its mechanism of action, Afatinib can cause fetal harm when administered to a pregnant woman. If you can become pregnant, use effective contraception during treatment, and for at least 2
weeks after the last dose of Afatinib.

• Gilotrif